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ABSTRACT
Introduction Multiple sclerosis (MS) is the most common 
cause of progressive neurological disability in young 
adults. The use of advance care planning (ACP) for people 
with progressive MS (pwPMS) remains limited. The 
ConCure- SM project aims to assess the effectiveness of a 
structured ACP intervention for pwPMS. The intervention 
consists of a training programme on ACP for healthcare 
professionals caring for pwPMS, and a booklet to be used 
during the ACP conversation. Herein, we describe the first 
two project phases.
Methods In phase 1 we translated and adapted, to the 
Italian legislation and MS context, the ACP booklet of the 
National ACP Programme for New Zealand. Acceptability, 
comprehensibility and usefulness of the booklet were 
assessed via 13 personal cognitive interviews with pwPMS 
and significant others (SOs), and one health professional 
focus group. Based on these findings, we will revise the 
booklet. In phase 2 we will conduct a single- arm pilot/
feasibility trial with nested qualitative study. Participants 
will be 40 pwPMS, their SOs, health professionals from 
six MS and rehabilitation centres in Italy. In the 6 months 
following the ACP conversation, we will assess completion 
of an advance care plan document (primary outcome), as 
well as safety of the intervention. Secondary outcomes will 
be a range of measures to capture the full process of ACP; 
patient- carer congruence in treatment preferences; quality 
of patient- clinician communication and caregiver burden. 
A qualitative process evaluation will help understand 
the factors likely to influence future implementation and 
scalability of the intervention.
Ethics and dissemination The project is coleaded by a 
neurologist and a bioethicist. Phase 1 has received ethical 
approvals from each participating centre, while phase 2 
will be submitted to the centres in May 2021. Findings 
from both phases will be disseminated widely through 
peer- reviewed publications, conferences and workshops.
Trial registration number ISRCTN48527663; Pre- results.
INTRODUCTION
With a lifetime risk of 1 in 400, multiple 
sclerosis (MS) is the most common cause of 
progressive neurological disability in young 
adults. Approximately 2.3 million people 
worldwide have MS, with Canada, the USA 
and some European countries, including 
Italy, having the highest prevalence rates.1 
Around 15% of people with MS have a 
primary progressive course at diagnosis, and 
a further 35% develop secondary progressive 
disease after 15 years.2 A mean reduction 
in life expectancy by 7–14 years has been 
reported in people with MS, with improved 
figures over the last two decades.3–5
Few treatment options are currently avail-
able to delay or prevent further clinical wors-
ening of people with primary or secondary 
progressive MS (pwPMS). They may live for 
many years experiencing a wide range of 
symptoms, impairments (including cogni-
tive impairment which affects 40%–70% of 
sufferers6) and comorbidities.5 7–10
Advance care planning (ACP) is a process 
that ‘enables individuals who have decisional 
capacity to identify their values, to reflect 
upon the meanings and consequences of 
serious illness scenarios, to define goals and 
preferences for future medical treatment 
and care, and to discuss these with family and 
healthcare professionals (HPs)’.11
Strengths and limitations of this study
 ► A strength of the study is the use of a mixed- 
methods approach.
 ► The intervention is coproduced with users.
 ► Study results will be key to inform the feasibility of a 
full- scale trial, and its design.
 ► A limitation is that the pilot trial is a non- randomised 
study.
 ► Long- term outcomes (chiefly concordance between 
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Consistently with the Shared Decision Making 
model,12–14 ACP involves both the patient and his/her 
HPs. Together, they make informed decisions about the 
patient’s (future) care. Also, the family can be involved in 
the process, if the patient wishes. ACP differs from general 
medical decision- making in that it is based on an antici-
pated deterioration in the health of a patient. It includes a 
focus on the person’s wishes and preferences for the time 
when they lose decisional capacity. In fact, it aims to align 
evidence- based practice and person- centred care15 using 
a bioethical focus to identify the patient’s values, prefer-
ences and desires. The planning process helps the patient 
to identify his/her personal values and goals, understand 
his/her health status, and the treatment and healthcare 
options available. Finally, ACP encourages discussion 
around end- of- life (EOL) care (a subject that is generally 
not considered part of healthcare planning, and one that 
can be avoided by both patients and HPs). It is up to the 
patient to determine the occurrence and content of any 
ACP discussion: if the patient does not wish to engage in 
conversations about his/her future care, this preference 
should be respected. The ACP process may result in the 
patient choosing to write an advance care plan document 
and to appoint a trustee (or else).
On 22 December 2017, the Italian Parliament approved 
the first law on EOL: ‘Provisions for informed consent 
and advance directives’ (L. 219/2017; http://www. trova-
norme. salute. gov. it/ norme/ dettaglioAtto? id= 62663). 
This law regulates advance directives (AD; Article 4) 
and ACP (Article 5), and a number of rights citizens 
have regarding healthcare issues, including the right to: 
be fully informed about one’s health status and to give 
consent (or dissent) to treatment; withhold consent to 
lifesaving treatments; be assisted until death. Moreover, 
the law states that the physician has a duty to respect 
the patient’s wishes. In a recent Italian survey, 88% 
(1752/2000) of citizens considered the Law 219/2017 
as quite or very important, and 76% had a positive atti-
tude towards making/registering AD or ACP.16 Impor-
tantly, this Law triggers HPs and healthcare authorities 
in promoting educational programmes on the topic, as 
well as programmes to implement ACP in daily clinical 
practice.
To optimise the alignment between patient preferences 
and values and the care they receive, HPs should inte-
grate best ACP practices in the care of pwPMS. A recent 
guideline on palliative care in MS found no evidence of 
the effects of ACP in pwPMS.17 However, there is some 
evidence from non- neurological progressive and life- 
threatening illnesses that ACP decreases the use of life- 
sustaining treatment, increases hospice/palliative care, 
reduces hospitalisations and increases alignment with 
patients’ EOL wishes.18 Furthermore, there is evidence 
that patients with MS and caregivers often would like 
to discuss the issues of death and dying and HPs should 
acknowledge and encourage these discussions.19 20 
However, often HPs leave EOL discussions until the later 
stages of progression in MS,21 and caregivers may be left 
having to take difficult decisions.22 A realist review iden-
tified two main barriers for ACP discussions taking place: 
the long and uncertain MS trajectory, with periods of 
stability punctuated by crisis; and lack of ACP communi-
cation skills and confidence of HPs.23
ConCure- SM is a project aimed to set up and evaluate 
the efficacy of an ACP intervention for pwPMS in Italy. 
The Shared Decision Making model described earlier 
is the theoretical framework of the project.12–14 The 
Medical Research Council framework for developing and 
evaluating complex interventions is the methodological 
framework of the project. The framework has a phased 
approach, from a preclinical research phase to a final 
phase in which the intervention is introduced into the 
health service, leading to a theory- driven intervention: 
a ‘bottom- up’ development which guarantees to enter 
a phase III trial with an appropriate theory and pilot 
work.24 Furthermore, both quantitative and qualitative 
methods are integrated within the framework, in order to 
better appraise the effects of the (complex) intervention 
both as a whole and on its components.
Our study hypotheses are that the intervention will 
produce: higher completion of an advance care plan 
document; increased congruence in treatment prefer-
ences between pwPMS and their carers; increased quality 
communication about EOL care.
METHODS AND ANALYSIS
The study protocol (FISM 2020/R- Multi/024; V.1.0; 
15 March 2021) was designed following the Stan-
dard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) guidelines (online supplemental 
appendix 1)25 and the SPIRIT- PRO Extension.26 The 
pilot/feasibility study follows the Consolidated Standards 
of Reporting Trials (CONSORT) guidance for trials on 
social and psychological interventions (CONSORT- SPI 
2018).27 It was registered on the ISRCTN registry on 30 
March 2021. Qualitative data will be reported following 
the Consolidated criteria for Reporting Qualitative 
research checklist.28
Figure 1 outlines the two project phases and inscribed 
actions. The red dot identifies the current advancement 
status.
Phase 1
The first project phase involves production of the ACP 
booklet (figure 1).
Provisional booklet
Early in 2020, an interdisciplinary panel translated into 
Italian and adapted to the MS context and to the Italian 
legislation, the ACP booklet of the Health Quality & Safety 
Commission’s New Zealand National ACP Programme 
(https://www. myacp. org. nz). The panel was made of five 
neurologists, one palliative care physician, one palliative 
care nurse, one psychologist, one bioethicist, one expert 
patient, one representative of the Italian MS Society and 
copyright.
 on A











pen: first published as 10.1136/bm





3De Panfilis L, et al. BMJ Open 2021;11:e052012. doi:10.1136/bmjopen-2021-052012
Open access
the author of the original booklet. The resulting booklet 
in its provisional version (online supplemental appendix 
2) consists of an introduction, a ‘guidance’ (the odd pages 
in most instances) and the advance care plan document 
(the even pages) to be completed electronically or manu-
ally by the pwPMS together with his/her referring physi-
cian. A significant other (SO), such as a family member, 
can participate in the process if requested by the pwPMS. 
The introduction explains the concepts of ACP and AD 
according to the Italian Law 219/2017, and describes why 
ACP is important in MS. Ten sections follow: ‘My Advance 
Care Plan’; ‘What matters to me’; ‘What worries me’; 
‘Why I’m making an Advance Care Plan’; ‘How I make 
decisions’; ‘If I were no longer able to make decisions: 
my trustee’; ‘Thinking about my EOL’; ‘My treatment and 
care choices’; ‘Signatures’; ‘Acronyms’. If the advance 
care plan document is completed, the pwPMS (and, 
when applicable, the pwPMS trustee) sign on page 29; the 
document is then scanned and stored, together with the 
completed booklet, in the (electronic) medical record.
Users’ assessment and revision
Between September and November 2020, the accept-
ability (contents, format, envisaged administration 
procedure), comprehensibility and usefulness of the 
provisional booklet were assessed by conducting 13 
personal cognitive interviews with pwPMS, pwPMS’ SOs 
and a focus group meeting (FGM) with HPs. Due to the 
COVID-19 pandemic, all the interviews and the FGM 
were held using digital platforms. Results of the qualita-
tive (thematic) analysis and the revision of the booklet 
are underway.
Phase 2
The second project phase will be dedicated to the conduc-
tion of the multi- centre, pilot and feasibility single- arm 
trial with a nested qualitative study. This phase (to be 
accomplished from May 2021 to November 2022) has 
three inscribed actions: intervention set up; pilot trial and 
qualitative study (figure 1).
Intervention set up
Training programme
The goal of this intervention is to prime HPs to discuss 
goals of care and ACP. To achieve this, HPs will attend a 
training programme (called Train- ConCure- SM) that will 
be Continuing Medical Education accredited, residential, 
and last one- and- half days (12 hours). The programme 
aims to: improve the HP knowledge, competencies and 
skills in ACP based on up- to- date scientific evidence; 
support and guide HPs in the ACP embedment in clinical 
practice; improve the communication between HPs and 
patient promoting an effective patient–practitioner part-
nership in decision- making.
The training will be interactive in style. Its residen-
tial nature and the use of role- playing exercises aim at 
supporting group discussion and the exchange of experi-
ences between participants.
It will consist of the following: one 2.5- hour theoretical 
session on the clinical, ethical and statutory principles of 
Shared Decision Making and ACP; two 4- hour empirical 
sessions (one on each day) on conducting ACP conversa-
tions in various clinical scenarios using the ConCure- SM 
booklet through guided role play exercises; two 45- min 
self- evaluation sessions (at the beginning and at the end 
of the training programme).
Trainees will be physicians and other HPs from the six 
enrolling centres. The Italian Law 219/2017 prescribes 
that ACP involves the patient, his/her referring physi-
cian and (when applicable) the trustee. We decided to 
train HPs other than physicians in order to promote 
ACP knowledge within the caring team. Each centre will 
provide 1–3 physicians, plus one HP from the following: 
MS nurse, therapist, psychologist or social worker. Thus, 
there will be 12–24 participants overall (2–4 from each 
centre). Trainers will be a panel of neurologists, psychol-
ogists, a palliative care physician, a palliative care nurse 
and a bioethicist. All have consolidated experience in 
leading training courses and workshops on patient–
clinician communication and Shared Decision Making, 
and four on ACP and EOL conversations. These four 
researchers will support physicians at the centres for 
issues concerning the conduction of the ACP conversa-
tion during the pilot trial.
Web platform
As part of the intervention set up action, a web- based 
trial platform will be created containing the pseudo- 
anonymised trial case record form (eCRF) and the 
outcome measures. The platform will be ID/password 
protected, with dedicated accesses based on the stake-
holder (pwPMS, SO, HPs, centre principal investigator 
(PI), interviewer, data manager) and operation (comple-
tion, consultation).
Figure 1 Flow chart of the ConCure- SM project. The red dot 
identifies the advancement status at the time of manuscript 
submission. FGM, focus group meeting; HP, health 
professional; MS, multiple sclerosis; NPT, normalisation 
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Linguistic validation of measures
Two outcome measures not available in Italian will 
be translated and cross- culturally adapted, following 
accepted guidelines29 30: the 4- item ACP Engagement 
questionnaire (4- item ACP- E)31 and the Quality of 
Communication Questionnaire (QOC).32 The main steps 
in this process are the following:
 ► Forward translation: two qualified translators, both 
living in Italy, will produce two independent transla-
tions. A panel consisting of the translators, two MS 
HPs and two lay persons will review the forward trans-
lations and a consensus version will be produced.
 ► Backward translation: the consensus translation gener-
ated in step 1 will be independently translated back 
into the source language by a third qualified trans-
lator, living in the target country. The backward trans-
lation will be produced without access to the original 
version and without consulting the other translators.
 ► Translation refinement: in a meeting between those 
participating in step 1 and the backward translator, 
the backward translation will be compared with 
the original, and further refinements to the Italian 
version will be made. Differences will be resolved by 
discussion.
 ► Each translated questionnaire will be proofread, and 
then administered to/debriefed with 5–10 patients.
Pilot and feasibility trial
The six centres involved in the pilot trial are located 
in northern (four centres), central and southern Italy 
(one centre each). Two of the centres are rehabilita-
tion hospitals (one of which a research hospital), three 
are MS centres (two university hospitals, one research 
hospital) and one is a rehabilitation and MS centre from 
a research hospital. Recruitment will be competitive, with 
no prespecified minimum number of enrolled subjects 
per centre. The maximum number of enrolled subjects 
per centre is 12.
There will be a baseline assessment (T0), an ACP 
conversation taking place within 1 month from the base-
line assessment, and a follow- up assessment within 1 
week of the ACP conversation (T1) and 6 months (T2) 
thereafter. The baseline and follow- up assessments will 
be performed via the web- based ConCure- SM platform. 
The physician will record on the platform subsequent 
ACP conversations that should occur during follow- up. 
Participants (pwPMS, SOs) will be free to withdraw from 
the study at any time, without giving reasons and with no 
risk of prejudicing future care. Study personnel will make 
every effort to obtain, and record, information about the 
drop out reasons.
The objectives of the pilot and feasibility trial are 
reported in box 1. trial procedures are summarised in 
figure 2.
Eligibility and screening
PwPMS (inpatients or outpatients) will be included if 
they are: ≥18 years of age; diagnosed with primary or 
secondary PMS33 one or more years before inclusion; able 
to communicate in Italian and gave written consent. In 
addition, one or more of the following conditions that 
would make ACP relevant must be present: expressed 
desire for ACP; questions about own future; thoughts 
about hastening death or medically assisted suicide; 
high risk for death within 2 years using the ‘Surprise 
Question’34; high risk for development of severe cogni-
tive compromise/dementia within 2 years; high risk for 
development of impairments preventing communication 
within 2 years; significant suffering (eg, uncontrolled 
physical symptoms, psychosocial or existential issues). 
PwPMS will be excluded if they have one or more of the 
following: severe cognitive compromise (MMSE <19) or 
impairments preventing communication; psychosis or 
other serious psychiatric conditions; advance care plan 
document completed.
PwPMS are recruited prospectively by the ACP- trained 
physicians involved in their care, when the potentially 
eligible pwPMS attends the centre for an outpatient visit 
or hospitalisation. PwPMS who show interest in partici-
pating receive full verbal and written information about 
the study purpose and procedures.
Baseline assessment (T0)
The ACP- trained physician makes an appointment with 
pwPMS who provided initial verbal consent to participate 
in the study, and checks all eligibility criteria. A written, 
signed informed consent is obtained, according to the 
Declaration of Helsinki and to the Good Clinical Practice 
(GCP) guidelines of the EU. The informed consent is kept 
on file by the study personnel, and is available for inspec-
tion by regulatory authorities or authorised persons.
Then, the physician gives the pwPMS the credentials to 
the trial platform, so that the pwPMS completes the base-
line set of questionnaires/instruments (completion time 
around 40 min). If the pwPMS has difficulties in using the 
trial platform, a telephone interview is scheduled within 
Box 1 Objectives of the pilot trial
 ► To determine how many people with progressive multiple sclerosis 
accept the invitation to participate in the study.
 ► To determine how many participants receive the intervention.
 ► To estimate recruitment and refusal rates, and 6- month follow- up 
rates.
 ► To estimate advance care planning (ACP) completion during the 
6- month follow- up (primary study outcome).
 ► To estimate occurrence of serious adverse events and adverse 
events during the 6- month follow- up.
 ► To assess, qualitatively, the acceptability of the recruitment pro-
cesses, assessments, intervention delivery and secondary outcome 
measures with key stakeholders.
 ► To measure changes in the secondary outcome measures.
 ► To explore the barriers and facilitators to implementing ACP in pw-
PMS, and the influence of the clinical setting.
 ► To inform the sample size estimation for a subsequent phase III trial, 
should this be feasible.
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a week with an independent, trained interviewer who will 
administer the questionnaires/instruments.
The ACP conversation is scheduled at the centre, within 
a month. It is the starting point of a process that is followed 
up during the study. However, for feasibility reasons and 
to adapt to participant needs, subsequent conversations 
are recorded, but not scheduled a priori. The pwPMS is 
invited to involve his/her SO (family member, relative or 
friend, who is next of kin or is key decision- maker as desig-
nated by the pwPMS and with whom the pwPMS shares 
his/her life). If the pwPMS agrees on involving his/her 
SO, the SO is contacted by a study researcher to confirm 
eligibility, explain the study and obtain verbal consent. 
Consenting SOs receive credentials to access the trial 
platform and complete the baseline set of questionnaires 
(completion time about 15 min). If the SO has difficulty 
Figure 2 Summary of trial procedures. ACP, advance care planning; ACP- E, ACP Engagement; eCPS, Control Preference 
Scale, electronic; EDSS, Expanded Disability Status Scale; HADS, Hospital Anxiety and Depression Scale; MSQOL-29, 29- 
item Multiple Sclerosis Quality of Life; OPTION, Observing Patient Involvement in Shared Decision Making; QOC, Quality of 
Communication; SO, significant other; ZBI, Zarit Burden Interview. Kurtzke58; Mahoney and Barthel.59
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in using the trial platform, a telephone interview is sched-
uled within a week with an independent, trained inter-
viewer who will administer the questionnaires.
Finally, the physician completes the eCRF via the trial 
platform.
Each centre will collect information on the number of 
pwPMS and SOs approached, screened and eligible prior 
to enrolment, with reasons for non- enrolment.
ACP conversation
The conversation involves the pwPMS, the ACP- trained 
physician involved in his/her care and, when appli-
cable, the SO. In addition, if the pwPMS agrees, the non- 
physician ACP- trained HP at the centre will participate. 
The first conversation takes place in a dedicated room 
at the centre, and is audio- recorded. At MS centres and 
rehabilitation centres, physician time and space are at 
premium, particularly for outpatient care. For this reason, 
1- hour slot is reserved for the conversation. In the case an 
SO participates it is envisaged that there will be a session 
closed to the SO, followed by an open session.
About 1 week before the scheduled ACP conversation, 
reminder emails (or telephone calls) are sent to pwPMS/
SOs. At the end of the ACP conversation, the physician 
invites the pwPMS (when applicable the SO) to complete 
the T1 follow- up assessment within 1 week. The physi-
cian completes the QOC- Doc immediately after the ACP 
conversation ends.
Follow-up assessments (T1, T2)
The pwPMS completes the questionnaires by 1 week 
(T1, assessment time of about 20 min) and 6 months 
(T2, assessment time of about 30 min) after the first 
ACP conversation using the trial platform. The SO 
completes the questionnaires/instruments (T1, assess-
ment time of about 20 min) using the trial platform. In 
the event the pwPMS/SO have difficulties in using the 
trial platform, a telephone interview is scheduled with an 
independent, trained interviewer who will administer the 
questionnaires/instruments.
About 1 week before the T2 assessment, reminder 
emails (or telephone calls) are sent to pwPMS. The physi-
cian completes the questionnaire (T1, QOC- Doc) and 
the eCRF using the trial platform. He/she records on the 
platform the date, duration, participants and mode (face 
to face, teleconference or on the telephone) of subse-
quent ACP conversations that occur during follow- up.
Outcome measures
A range of measures will be collected to capture the full 
process of ACP and whether the ConCure- SM interven-
tion has any effect on completion of an advance care plan 
document (primary outcome measure), congruence in 
treatment preferences between pwPMS and their carers, 
quality of patient–clinician communication and care-
giver burden (table 1). In addition, since a study- related 
increase in emotional burden can not be excluded, 
serious adverse events (admission to psychiatric ward, 
suicide attempt, death) will be monitored by the indepen-
dent Data and Safety Monitoring Committee (DSMC).
We will use the published Italian version of the following 
inventories: Control Preference Scale (CPS)35; Hospital 
Anxiety and Depression Scale (HADS)36; Observing 
Patient Involvement in Decision Making (OPTION)37; 
29- item Multiple Sclerosis Quality of Life (MSQOL)−2938; 
Zarit Burden Interview (ZBI).39 The 4- item ACP- E and 
the QOC inventories will be translated/culturally adapted 
from the source language (see previously).
ACP engagement
The ACP process will be assessed using the 4- item ACP- E 
questionnaire.31 Originally developed and validated to 
measure the complex behaviour of ACP, the question-
naire is available in four versions (55- item, 34- item, 9- item, 
4- item). In this study, we will use the 4- item version which 
focuses on the readiness behaviour change construct 
Table 1 Secondary outcome measures of the trial (in alphabetical order)
Scale name Assessor Construct Author Italian version Timing
4- item ACP- E Patient ACP engagement   Sudore et al31 – T0/T1/T2
eCPS Patient Role preferences   Degner et al40 Solari et al42 T0
HADS Patient Mood symptoms   Zigmond and 
Snaith44
Costantini et al36 T0/T1/T2
MSQOL-29 Patient Health- related QOL   Rosato et al38 Rosato et al38 T0/T2
OPTION Third observer Shared Decision Making (physician’s kills)   Elwyn et al43 Goss et al37 –
QOC Patient Communication quality (physician’s skills)   Engelberg et al32 – T1
QOC- Doc Physician Communication quality (physician’s skills)   – – T1
QOC- SO SO Communication quality (physician’s skills)   – – T1
ZBI SO Caregiver burden   Hérbert et al46 Chattat et al39 T0/T1/T2
ACP- E, Advance Care Planning Engagement; eCPS, Control Preference Scale, electronic; HADS, Hospital Anxiety and Depression Scale; 
MSQOL-29, 29- item Multiple Sclerosis Quality of Life; OPTION, Observing Patient Involvement in Shared Decision Making; QOC, Quality of 
Communication; SO, significant other; ZBI, Zarit Burden Interview.
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within the quality of life ACP domain. Responses are on a 
5- point Likert scale ((1) ‘I have never thought about it’; 
(2) ‘I have thought about it, but I am not ready to do it’; 
(3) ‘I am thinking about doing it in the next 6 months’; 
(4) ‘I am definitely planning to do it in the next 30 days’; 
(5) ‘I have already done it’).31
Role preferences
The CPS is the most used instrument to assess patient 
preferences for involvement in decisions about their 
health.40 41 It consists of five ‘cards’ on a board, each 
illustrating a different role in decision- making by means 
of a cartoon and short descriptive statement. In its orig-
inal version, administration requires a trained exam-
iner, who asks the patient to choose the preferred card, 
which is then covered up. The procedure continues (four 
choices) until one card is left. If the second preference 
is incongruent with the first (non- adjacent pairing, such 
as card A with card C), the test is explained again, and 
immediately readministered. In the event of a further 
incongruence, the test is not readministered, and a pref-
erence is not assigned. Six scores are possible based on 
the subject’s two most preferred roles: active–active, 
active–collaborative, collaborative–active, collaborative–
passive, passive–collaborative and passive–passive. These 
scores are grouped as: active (active–active or active–
collaborative), collaborative (collaborative–active or 
collaborative–passive) or passive (passive–collaborative or 
passive–passive).40 We will use the electronic, Italian self- 
administered CPS.42
Quality of the conversation
We will assess the quality of the first ACP conversation 
considering three perspectives: an independent observer, 
the pwPMS, and the physician. Each conversation will 
be unobtrusively audio- taped and transcribed verbatim; 
subsequently, a specially trained third observer will eval-
uate the behaviour of the physician in terms of patient 
involvement in decision- making using the OPTION 
(http://www. glynelwyn. com/ observer- option- instru-
ment. html).43 The OPTION consists of 12 items, each 
rated on a 5- point Likert scale ranging from 0 (behaviour 
not observed) to 4 (behaviour observed to high stan-
dard). A total score (range 0–48) is obtained by adding 
the scores of each item. After the ACP conversation, 
pwPMS will complete the QOC32; SOs will complete the 
SO version (QOC- SO), and physicians the physician 
version (last two items) of the QOC. Developed from 
qualitative studies with patients, families and clinicians, 
the QOC consists of 19 items measuring general commu-
nication (9 items) and communication about EOL care 
(8 items), each rated on a scale from 0 (‘very worst I can 
imagine’/‘not at all’) to 10 (‘very best I can imagine’/‘ex-
tremely’), or identified as something the clinician did not 
do. The 0/10 ratings are recoded to 1/11, with 0 imputed 
for ‘did not do’ (http:// depts. washington. edu/ eolcare/ 
products/ instruments/).
Other outcome measures
PwPMS quality of life will be assessed using the electronic 
version of the MSQOL-29, which is the shortened form of 
the MSQOL-54.38 MSQOL-29 includes 25 items forming 
7 subscales and 4 single items, and 1 filter question for 3 
‘sexual function’ items. Mood symptoms will be assessed 
with the HADS, a self- assessed questionnaire consisting 
of 14 multiple- choice (0–3 Likert scale) items probing 
symptoms of anxiety (7 items) and depression (7 items). 
HADS anxiety (HADS- A) and depression (HADS- D) 
scores range from 0 (no symptoms) to 21 (most severe 
symptoms).44 A cut- off score of 8 or above was recom-
mended for patients with MS, since it was found to be 
an accurate indicator of major depression (90% sensi-
tivity, 87% specificity) and generalised anxiety disorder 
(88.5% sensitivity; 81% specificity) in this population.45 
Finally, SO burden will be assessed using the ZBI,46 a 
22- item self- report measure of subjective burden among 
caregivers addressing functional and behavioural impair-
ments as well as the home care circumstances. A total 0 
(low burden) to 88 (high burden) score is obtained by 
summing item responses, each scored on a 5- point Likert 
scale ranging from 0 (never) to 4 (nearly always present).
Meetings
There will be two study meetings (teleconferences): the 
investigators’ meeting will be held before enrolment 
starts. Participants will be the Steering Committee, the 
centre PIs and the HPs who participated in the training 
programme. The aim of this meeting is to provide clear 
information on the study procedures, and to train HPs 
on the use of the trial platform. A second meeting will 
be run about 2 months after enrolment starts, in order 
to monitor possible difficulties, top- up centres’ motiva-
tion and provide a safe place for peer discussion on the 
implementation of the intervention. Both meetings will 
last about 2 hours. Additional meetings will be organ-
ised whenever needed. In addition, the study PIs and the 
Training Panel will be available for inquiries about the 
implementation of the intervention at the participating 
centres.
Nested qualitative study
We will perform one- on- one semi- structured interviews 
with pwPMS and SOs, chosen using a maximum varia-
tion strategy, and FGMs of HPs involved in intervention 
delivery. For pwPMS and SOs interviews were considered 
most appropriate to limit interview burden and hopefully 
make it easier for participants to express their feelings, 
and recount their experiences of the intervention. For 
the patient referring physicians and the other HPs we 
chose FGMs as they promote interaction and exchange 
of ideas. A minimum of 10 interviews (five with pwPMS 
and five with SOs) and two FGMs will be held, the final 
number depending on the achievement of ‘data satura-
tion’.47 Interviews and FGMs will be run via video tele-
conference, which will ease participation of pwPMS with 
severe disability and SOs with caregiving commitments, as 
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well as HPs. If the pwPMS and/or SOs have no access to 
internet using personal computer or other devices, such 
participants will be interviewed on the telephone.
The interviews aim to provide important feedback on 
participant perception of the quality of the intervention 
provided, and will serve as a process measure. Insights 
from this qualitative analysis will serve to inform fine- 
grain intervention refinement. They will take place 
within 2 months of trial completion, and last no more 
than an hour. To reduce social desirability response bias, 
the interviewers will be researchers not involved in the 
ConCure- SM intervention delivery. Before starting, inter-
viewees will be informed of study aims and requirements, 
and provide written consent. The interviewer will then 
explain that the aim of the interview is to obtain partici-
pant feedback on experience of the pilot study and stress 
that positive and negative experiences of, and feelings 
about, the intervention are welcome. Participants will be 
assured that the interviews are confidential, and that the 
audio recordings and subsequent transcripts will be fully 
anonymised. The interviewer will then pose each ques-
tion in turn, neutrally (so as to not suggest any partic-
ular reply) and in an open- ended fashion (to allow many 
possible replies). As each question is discussed, follow- up 
questions will clarify and explore participant responses. 
Participants will be also encouraged to elaborate on any 
pertinent themes or views that emerge. The interviewer 
will note any potentially informative non- verbal gestures. 
At the end of the interview, the interviewer will verbally 
summarise the key points and ask the participant if the 
summary is full and correct.
The FGMs aim to collect insights and living experiences 
about the intervention and to identify possible barriers to 
its implementation; they will provide important feedback 
on the intervention and on factors that can enable its 
implementation and adoption. For this reason, HPs other 
than the physicians involved in the ACP conversation will 
be involved. Each FGM (teleconference) will last about 2 
hours; participants will be 6–10 physicians who delivered 
the intervention and HPs from the participating centres. 
All participants will provide written informed consent 
prior to the FGM, that will be conducted by two psychol-
ogists specifically trained in qualitative research. One will 
be the facilitator, whose job is to engage all participants, 
promote exchange, moderate conflicts, ensure that all 
prespecified topics will be adequately covered, and allow 
exploration of any pertinent issues that arise. He/she will 
first explain the purpose of the meeting and ask partic-
ipants to introduce themselves. He/she will then intro-
duce each topic in turn, in an open- ended fashion. At any 
point, the facilitator can probe for further information 
and ask follow- up questions to stimulate further discus-
sion. After all prespecified topics are fully discussed, the 
facilitator will summarise the main points, and ask for 
further feedback and whether all concerns have been 
fully aired. The comoderator will take notes and oversee 
the audio recording. Subsequently, they will produce a 
report from the audio recordings/transcript and field 




As this is a pilot and feasibility study, a formal sample size 
calculation is not required. We aim to recruit at least 40 
pwPMS from six centres to assess feasibility across a diverse 
range of participants including those with different care 
needs and living conditions. There are no data available 
on the occurrence of ACP in pwPMS: by hypothesising a 
proportion in the pwPMS population of 10%, a sample 
size of 35 subjects achieves a power of 90%, assuming a 
type I error of 5%, to detect a proportion of ACP docu-
mentation of 30%. By hypothesising a proportion in the 
pwPMS population of 8%, a sample size of 35 subjects 
achieves a power of 95%, assuming a type I error of 5%, 
to detect a proportion of ACP documentation of 30%. By 
adding 15% of drop outs or incomplete data, 40 pwPMS 
should be recruited.
Statistics
Descriptive statistics will be calculated for general and 
clinical variables. Specifically, continuous variables will be 
summarised by their mean and SD, or median and IQR; 
categorical variables will be summarised as numbers and 
percentages. Categorical variables will be compared using 
the χ2 test. The normality assumption of continuous vari-
ables will be tested with the Shapiro- Wilk test. Depending 
on data distribution, between- group comparisons will be 
carried out using either the two- sided unpaired t- test or 
the Wilcoxon two- sided two sample test; within- group 
comparisons will be carried out using either the paired 
t- test or the Wilcoxon signed- rank test; correlations will 
be computed using Pearson’s or Spearman’s coefficients.
Our primary end- point is the proportion of pwPMS 
completing an ACP during the 6- month period. Change 
in the secondary outcome measures will be also calcu-
lated. In addition, we will calculate the following feasi-
bility outcomes: recruitment rate (enrolment per month; 
reasons for non- eligibility, non- enrolment); retention 
rate (proportion completing the intervention and study 
follow- up); missing data (proportion fully completed, 
for each scale, at each time point). Data will be analysed 
according to the intention- to- treat principle. Multiple 
imputation of missing values will employ Rubin’s 
approach. A p value less than 0.05 will be considered statis-
tically significant. No correction for multiple compari-
sons will be applied. All analyses will be performed using 
STATA V.16. Assumptions in determining the sample size 
of the main trial will be checked.
Qualitative data
Interviews and FGMs will be audio- recorded and tran-
scribed verbatim. Data analysis will be conducted by 
three researchers with experience in qualitative research. 
Researchers will analyse interviews and FGM data using 
thematic analysis, with interpretation guided by the four 
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normalisation process theory (NPT) components (see 
process evaluation below). Data will be triangulated 
across sources. The analytical stages can be summarised 
as follows48: (1) each researcher will read the transcrip-
tions and write comments and initial thoughts in a 
memo. (2) Each researcher will extract portions of the 
text individually and then share their work to reach an 
initial agreement. During this stage, they will conduct 
the thematic analysis inductively providing their insights. 
(3) Researchers will independently review themes and 
allocate portions of the text to the newly reconfigured 
themes. (4) Together, they will redefine themes and 
rename them to achieve internal consistency. (5) One 
researcher will extract from the interviews and draft the 
final report, which will be checked and amended by the 
other two.
Process evaluation
We will follow the Medical Research Council guidance 
on process evaluation,49 which describes three compo-
nents using a mixed- methods approach: implementation 
or delivery; mechanisms of impact; contextual factors. 
We will use NPT to determine if, and in what ways, the 
ConCure- SM intervention can be successfully ‘normalised’ 
(embedded) into clinical practice.50 51 At the feasibility 
and piloting stage, basic quantitative measures of imple-
mentation may be combined with in- depth qualitative 
data to provide detailed understandings of intervention 
functioning on a small scale.49 Quantitative measures will 
include structured observations of audio- recorded ACP 
conversations. These will be used to examine aspects of 
fidelity (such as consistency with the Shared Decision 
Making principles), and dose (the duration of conver-
sations). Qualitative methods will be used to investigate 
mechanisms of impact and contextual factors, using NPT. 
NPT identifies four essential determinants of ‘normal-
ising’ complex interventions into common practice: 
coherence (the extent to which an intervention is under-
stood as being meaningful, achievable and valuable); 
cognitive participation (the engagement of HPs necessary 
to deliver the intervention); collective action (the work that 
brings the intervention into use) and reflexive monitoring 
(the on- going process of adjusting the intervention to 
keep it in place).51 These components are considered to 
be dynamic and interact within the wider context of the 
intervention, such as existing organisational structures 
and procedures.51 Further, we will use qualitative data 
to identify required modifications and to develop prac-
tical strategies for enabling and sustaining intervention 
delivery in clinical settings.
Patient and public involvement statement
An expert patient with MS and a representative of the 
Italian MS Society are part of the Steering Committee of 
the project and coauthors of the present paper. These 
same persons were part of the interdisciplinary panel that 
produced the ACP booklet, which was revised based on 
the results of a qualitative study with users (pwPMS, SOs 
and HPs).
Prior to designing and conducting a full trial, the 
intervention will be pilot tested in a multicentre study 
involving MS and rehabilitation centres across Italy, and 
using a mixed- method approach.
We will disseminate key study findings to pwPMS via the 
Italian MS Society.
Ethics and dissemination
The project is coleaded by a neurologist and a bioethi-
cist. Phase 1 has received ethical approvals from each 
participating centre, while phase 2 will be submitted to 
the centres in May 2021. Findings from both phases will 
be disseminated widely through peer- reviewed publica-
tions, conferences and workshops. Authorship eligibility 
will be based on The International Committee of Medical 
Journal Editors. The final trial (pseudo- anonymised) 
dataset will be accessed by the study PIs and the data 
management/analysis team. Details about panels and 
centres, ethics and administrative considerations, and 
study management and monitoring are available in 
online supplemental appendix 3.
DISCUSSION
One of the 10 clinical questions of the European Academy 
of Neurology (EAN) guideline on palliative care of 
pwPMS specifically addressed ACP.17 For this clinical 
question, formulated with direct patient and caregiver 
involvement,52 no evidence was found and two good prac-
tice statements were produced: ‘It is suggested that early 
discussion of the future with ACP is offered to patients 
with severe MS’; ‘It is suggested that regular communi-
cation about the future progression of MS is undertaken 
with patients and families/caregivers’.17 To fill this knowl-
edge gap, we conceived the present study, which adheres 
to the Shared Decision Making model,12–14 and to the 
Medical Research Council framework for developing and 
evaluating complex interventions.24 Within this method-
ological context, the study follows the CONSORT guid-
ance for trials on social and psychological interventions 
(CONSORT- SPI 2018),27 as many of the guidance items 
(excluding items that are specific to the randomisation 
nature of the study) are relevant for reporting other 
types of pilot and feasibility studies.53 This includes the 
development of the study protocol following the SPIRIT 
guidance,26 protocol’s publication and the trial public 
registration (ISRCTN registry). The consolidated criteria 
for reporting qualitative research will guide the presenta-
tion of findings in the study reports and publications.28 54
To increase generalisability of the study, participants 
(pwPMS, SOs and HPs) will be enrolled from university 
hospitals, research hospitals and clinical centres from the 
different areas of Italy. We will not enrol from primary 
care practices as in Italy patients with MS are followed 
in tertiary care centres. Moreover, previous attempts to 
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involve the family physicians in the care of PwPMS were 
challenging.55
Personal, semi- structured interviews and FGMs will be 
run via video teleconference, which will ease participa-
tion of pwPMS with severe disability and SOs with care-
giving commitments, as well as HPs. If pwPMS and/or 
SOs have no internet access, using personal computer or 
other devices, these participants will be interviewed on 
the telephone. Other measures adopted to minimise bias 
include: all study personnel will be trained to conform to 
GCP regulation; electronic version of the study question-
naires/inventories will be used to ensure the data entered 
is of high quality; an DSMC will monitor and supervise 
the progress of the trial, and the safety data.
The ConCure- SM intervention (booklet and HP 
training programme) can be adapted for use in other 
neurological and non- neurological conditions for which 
consolidated ACP interventions are not available. The 
electronic format will ease the incorporation of the 
advance care plan document (and its updates) in the 
electronic medical record, that is currently available in 
some Italian regions and hopefully will be soon available 
all over Italy.
Study limitations
Three study limitations are noted. We used a single- arm 
design for the pilot trial. This decision was taken as 
ACP is currently at premium in MS,17 23 and designing 
a randomised (cluster) trial with standard care or any 
‘low intensity’ intervention as a comparator was consid-
ered ethically and practically unviable. Another limita-
tion is that our training programme was for HPs only. A 
multiple- component intervention that targets clinicians 
and patients simultaneously has been suggested in other 
disciplines.56 In the current situation regarding ACP, 
we preferred to have a clear focus on enhancing HP 
competencies.17 23 Finally, our pilot trial lacks long- term 
outcomes, chiefly the concordance between preferred 
and received EOL care and treatments.57 However, the 
MS trajectory further challenges the collection of this 
outcome in the typical timeframe of a clinical trial. In line 
with the principles of ACP, we agreed not to narrow the 
inclusion criteria only to pwPMS in the late stage of the 
disease, deserving this relevant outcome to future studies.
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